TMPRSS2 and prostate cancer: Importantly, prostate cancer-associated SPOP mutants fail to induce ERG degradation, whereas the majority of TMPRSS2-ERG fusions encoding N-terminal truncated ERG proteins are resistant to SPOP-mediated degradation.